Status:
COMPLETED
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
Lead Sponsor:
Takeda
Conditions:
Breakthrough Pain
Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks. The fent...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- decision to start treatment with intranasal fentanyl spray
- written informed consent
- Exclusion criteria:
- criteria as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.3)
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
131 Patients enrolled
Trial Details
Trial ID
NCT00994760
Start Date
September 1 2009
End Date
November 1 2010
Last Update
September 27 2012
Active Locations (168)
Enter a location and click search to find clinical trials sorted by distance.
1
Nycomed Deutschland GmbH
Aachen, Germany, 52074
2
Nycomed Deutschland GmbH
Adendorf, Germany, 21365
3
Nycomed Deutschland GmbH
Aichach, Germany, 86551
4
Nycomed Deutschland GmbH
Albstadt, Germany, 72458